Cutler Group LP Relmada Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$2.17 - $35.84 $53,816 - $888,832	24,800 Added 539.13%	29,400 $0
Q3 2022 Oct 25, 2022	SELL	$18.3 - $37.02 $38,430 - $77,742	-2,100 Reduced 31.34%	4,600 $64,000
Q2 2022 Aug 04, 2022	SELL	$16.5 - $30.34 $143,550 - $263,958	-8,700 Reduced 56.49%	6,700 $9,000
Q1 2022 Apr 14, 2022	BUY	$16.72 - $26.99 $183,920 - $296,890	11,000 Added 250.0%	15,400 $122,000
Q2 2021 Jul 19, 2021	BUY	$29.55 - $39.15 $70,920 - $93,960	2,400 Added 120.0%	4,400 $16,000
Q3 2020 Oct 27, 2020	SELL	$34.42 - $43.78 $209,962 - $267,058	-6,100 Reduced 75.31%	2,000 $6,000
Q2 2020 Jul 22, 2020	BUY	$31.59 - $49.98 $170,586 - $269,892	5,400 Added 200.0%	8,100 $30,000
Q1 2020 May 07, 2020	BUY	$23.78 - $50.12 $14,268 - $30,072	600 Added 28.57%	2,700 $4,000
Q4 2019 Feb 06, 2020	BUY	$10.1 - $47.18 $21,210 - $99,078	2,100 New	2,100 $17,000

11.5M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.